Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Standard Biotools (LAB) Long-Term Deferred Tax (2024 - 2025)

Standard Biotools (LAB) has disclosed Long-Term Deferred Tax for 2 consecutive years, with $341.2 million as the latest value for Q4 2025.

Quarterly Long-Term Deferred Tax rose 2409.02% to $341.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $341.2 million through Dec 2025, up 2409.02% year-over-year, with the annual reading at $341.2 million for FY2025, 2409.02% up from the prior year.
Long-Term Deferred Tax for Q4 2025 was $341.2 million at Standard Biotools, up from $13.6 million in the prior quarter.
The five-year high for Long-Term Deferred Tax was $341.2 million in Q4 2025, with the low at $13.6 million in Q4 2024.